American Journal of Cardiology
Volume 102, Issue 6, Supplement , Pages 12H-19H , 22 September 2008

New Horizons in Antiarrhythmic Therapy: Will Novel Agents Overcome Current Deficits?

References 

  1. Lévy S. Do we need pharmacological therapy for atrial fibrillation in the ablation era?. J Interv Card Electrophysiol. 2006;17:189–194
  2. Page RL. Medical management of atrial fibrillation: future directions. Heart Rhythm. 2007;4(suppl):S90–S94
  3. Camm J. Medical management of atrial fibrillation: state of the art. J Cardiovasc Electrophysiol. 2006;17(suppl 2):S2–S6
  4. Lombardi F, Terranova P. Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs. Curr Medicinal Chem. 2006;13:1635–1653
  5. Hohnloser SH, Dorian P, Straub M, Beckmann K, Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol. 2004;44:99–104
  6. Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007;41:599–605
  7. Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD. New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther. 2007;5:707–714
  8. Page RL, Connolly SJ, Wilkinson WE, Marcello SR, Schnell DJ, Pritchett ELC. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. Am Heart J. 2002;143:643–649
  9. Page RL, Tilsch TW, Connolly SJ, Schnell DJ, Marcello SR, Wilkinson WE, et al. Asymptomatic or “silent” atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation. 2003;107:1141–1145
  10. Pritchett EL, Kowey P, Connolly S, Page RL, Kerr C, Wilkinson WE. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation: maintenance of sinus rhythm after conversion to sinus rhythm. Am Heart J. 2006;151:1043–1049
  11. Lombardi F, Borggrefe M, Ruzyllo W, Lüderitz B. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. Eur Heart J. 2006;27:2224–2231
  12. Kerr CR, Connolly SJ, Kowey P, Page RL, Pritchett EL, Ruda MY, et al. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol. 2006;98:215–218
  13. Kowey PR, Stoenescu ML. Selection of drugs in pursuit of a rhythm control strategy. Prog Cardiovasc Dis. 2005;48:139–145
  14. Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and rate-controlling effects. J Cardiovasc Electrophysiol. 2006;17(suppl 2):S17–S20
  15. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987–999
  16. Hohnloser SH, Connolly SJ, Crijns HJ, Page RL, Seiz W, Torp-Petersen C. Rationale and design of ATHENA: A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg Bid for the Prevention of Cardiovascular Hospitalization or Death from any cause in Patients with Atrial Fibrillation/Atrial Flutter. J Cardiovasc Electrophysiol. 2008;19:69–73
  17. Hohnloser SH. Effects of dronedarone on cardiovascular outcomes in high-risk patients with atrial fibrillation or atrial flutter: the results of the ATHENA trial. Late-breaking clinical trial presented at the Heart Rhythm Society; May 15, 2008; San Francisco, California.
  18. Wijffels MCEF, Crijns HJGM. Recent advances in drug therapy for atrial fibrillation. J Cardiovasc Electrophysiol. 2003;14(suppl):S40–S47
  19. Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004;44:2355–2361
  20. No authors listed Vernakalant: RSD 1235, RSD-1235, RSD1235. Drugs R D. 2007;8:259–265
  21. Roy D, Pratt C ACT I Investigators. RSD1235 for conversion of atrial fibrillation. The Phase III Atrial Arrhythmia Conversion Trial. Program and abstracts from the Heart Rhythm 2005 26th Annual Scientific Sessions; May 4-7, 2005; New Orleans, Louisiana. http://www.conferencearchives.net/hrs2005/sessions/CC38.2/session.htmlAccessed September 6, 2007
  22. Kowey PR, Roy D, Pratt CM, Schwartz PJ, Dorian P, Mitchell LB, et al. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular and coronary artery bypass surgery. Circulation. 2007;116:II636–II637Abstract 2860
  23. Haugan K, Olsen KB, Hartvig L, Petersen JS, Holstein-Rathlou N-H, Hennan JK, et al. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J Cardiovasc Electrophysiol. 2005;16:537–545
  24. Lally JA, Gnall EM, Seltzer J, Kowey PR. Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18:1222–1228
  25. Pedersen OD, Bagger H, Køber L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376–380
  26. Vermes E, Tardif J-C, Bourassa MG, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003;107:2926–2931
  27. Madrid AH, Escobar C, Rebollo JMG, Marín I, Bernal E, Nannini S, et al. Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the Irbesartan-Amiodarone trial. Card Electrophysiol Rev. 2003;7:243–246
  28. Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, et al Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm. 2004;1:669–675
  29. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003;92:1379–1383
  30. Siu C-W, Lau C-P, Tse H-F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol. 2003;92:1343–1345
  31. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2004;93:780–782
  32. Calò L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol. 2005;45:1723–1728
  33. ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet. 2006;367:1903–1912
  34. Verheugt FWA. Good old warfarin for stroke prevention in atrial fibrillation. [comment] Lancet. 2006;367:1877–1878
  35. AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109:1509–1513
  36. Crijns HJGM. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say. Drugs. 2005;65:1651–1667

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)01081-3

doi: 10.1016/j.amjcard.2008.06.025

American Journal of Cardiology
Volume 102, Issue 6, Supplement , Pages 12H-19H , 22 September 2008

Article Tools

* Image Usage & Resolution